Evidence map›Paper›PMID 24876115›Full record

ArticleJournal of the American Society of Nephrology : JASN2014

CKD and the risk of incident cancer.

William T Lowrance, Juan Ordoñez, Natalia Udaltsova, Paul Russo, Alan S Go

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 4 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 4 syntheses or guidelines pooled it, 269 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Chronic kidney disease and risk of kidney or urothelial malignancy: systematic review and meta-analysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

William T LowranceHuntsman Cancer Institute, Division of Urology, University of Utah, Salt Lake City, Utah;
Juan OrdoñezDepartment of Nephrology, Kaiser Permanente Oakland Medical Center, Oakland, California;
Natalia UdaltsovaDivision of Research, Kaiser Permanente Northern California, Oakland, California;
Paul RussoDepartment of Surgery-Urology Service, Memorial Sloan-Kettering Cancer Center, New York, New York;
Alan S GoDivision of Research, Kaiser Permanente Northern California, Oakland, California; Departments of Epidemiology, Biostatistics and Medicine, University of California, San Francisco, California; and Department of Health Research and Policy, Stanford University, Stanford, California alan.s.go@kp.org.
Kaiser Permanente · USKaiser Permanente Oakland Medical Center · USMemorial Sloan Kettering Cancer Center · USUniversity of Utah · US

Funding

Study of the Care and Outcomes of REnal InsufficiencyU01DK060902 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI GO, ALAN S · 2001 to 2025
$19.5M
UROLOGY ONCOLOGY RESEARCH TRAINING GRANTT32CA082088 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Brett Stewart Carver · 1999 to 2026
$7.1M
A pilot trial of an intervention to support initial type 2 diabetes selfmanagement among younger adults with children.R01DK139225 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI Anjali Gopalan · 2025 to 2026
$649k
NCI NIH HHS T32 CA082088NCI NIH HHS T32-CA82088NIDDK NIH HHS R01 DK139225NIDDK NIH HHS U01 DK060902NIDDK NIH HHS U01-DK060902
6 · The paper itself

Abstract

Previous studies report a higher risk of cancer in patients with ESRD, but the impact of less severe CKD on risk of cancer is uncertain. Our objective was to evaluate the association between level of kidney function and subsequent cancer risk. We performed a retrospective cohort study of 1,190,538 adults who were receiving care within a health care delivery system, had a measurement of kidney function obtained between 2000 and 2008, and had no prior cancer. We examined the association between level of eGFR and the risk of incident cancer; the primary outcome was renal cancer, and secondary outcomes were any cancer and specific cancers (urothelial, prostate, breast, lung, and colorectal). During 6,000,420 person-years of follow-up, we identified 76,809 incident cancers in 72,875 subjects. After adjustment for time-updated confounders, lower eGFR (in milliliters per minute per 1.73 m(2)) was associated with an increased risk of renal cancer (adjusted hazard ratio [HR], 1.39; 95% confidence interval [95% CI], 1.22 to 1.58 for eGFR=45-59; HR, 1.81; 95% CI, 1.51 to 2.17 for eGFR=30-44; HR, 2.28; 95% CI, 1.78 to 2.92 for eGFR<30). We also observed an increased risk of urothelial cancer at eGFR<30 but no significant associations between eGFR and prostate, breast, lung, colorectal, or any cancer overall. In conclusion, reduced eGFR is associated with an independently higher risk of renal and urothelial cancer but not other cancer types.

Indexed as

AdultAgedAged, 80 and overCaliforniaCohort StudiesFemaleHumansIncidenceKidney NeoplasmsMaleMiddle AgedNeoplasmsRenal Insufficiency, Chronic

Identifiers

PMID24876115
PMCPMC4178430
OpenAlexW2135658710

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.